

PCR-/NAT *Chlamydia pneumoniae* (RV 540) Nov 2025



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

Proben Nr.	Erwartet / expected		Probenzusammensetzung / Sample composition
540A 251014 01	+++	61	<i>Chlamydia pneumoniae</i> (~ 1x10 ⁵ IFU/mL)
540A 251014 02	++	61	<i>Chlamydia pneumoniae</i> (~ 1x10 ⁴ IFU/mL)
540A 251014 03	Ø	62	<i>Escherichia coli</i> K12
540A 251014 04	Ø	62	<i>Legionella pneumophila</i> (~ 5x10 ⁵ CFU/mL)

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

<i>n</i> = 145		Proben Nr. (Sample no.)				Inhibition				
Befund Result		01	02	03	04		01	02	03	04
Positiv	145	145	145	0	1	n.d.	1	1	1	1
Negativ	0	0	0	145	144	nein no	144	144	144	144
Fraglich Questionable	0	0	0	0	0	ja yes	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number)	NAT richtig positiv True positive results				NAT richtig negativ True negative results			
	01		02		03		04	
	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%
AID CAP Bac PCR Kit (= 3)	3	100	3	100	3	100	3	100
ARGENE Chla/Myco pneumo R-GENE (= 5)	5	100	5	100	5	100	5	100
Amplex eazplex PneumoBug expert (n= 3)	3	100	3	100	3	100	3	100
AmpliGnost C. pneumoniae (n= 3)	3	100	3	100	3	100	3	100
AmpliSens M. pn. /C. pn. FRT PCR kit (n= 2)	2	100	2	100	2	100	2	100
AusDiagnostics Resp. Pathogens 24-well (n= 1)	1	100	1	100	1	100	1	100
BioGx auf BD Max (n= 8)	8	100	8	100	8	100	8	100
BioFire FILMARRAY Resp. Panel 2.1 plus (n= 2)	2	100	2	100	2	100	2	100

Biologio ReadyMax b-CAP Assay (n= 2)	2	100	2	100	2	100	2	100
CerTest VIASURE C.pn, M.pn, L.pn (n= 2)	2	100	2	100	2	100	2	100
GeneProof C. pneumoniae (n= 9)	9	100	9	100	9	100	9	100
Luminex Resp. Pathogen Multiplex (n= 4)	4	100	4	100	4	100	4	100
ampliCube Resp. panel 1.1 / 1.1LC (n = 14)	14	100	14	100	14	100	14	100
QIAstat-Dx Resp. Sars CoV-2 panel (n= 3)	3	100	3	100	3	100	3	100
Roche UC-TIB-Respi-BAC-2 (n= 7)	7	100	7	100	7	100	7	100
Sacace M.pn. /C. pn. Real-TM (n= 1)	1	100	1	100	1	100	1	100
Seegene Allplex Pneumobacter (n= 18)	18	100	18	100	18	100	18	100
Seegene Allplex Resp. Panel 4 (n= 20)	20	100	20	100	20	100	20	100
TIB Molbiol LightMix C. pneumoniae (n= 5)	5	100	5	100	5	100	5	100
r-Biopharm RIDAGENE CAP Bac (n= 5)	5	100	5	100	5	100	5	100
In house PCR assay (n= 17)	17	100	17	100	17	100	17	100
Other commercial tests (n= 11)	11	100	11	100	11	100	10	91

Comments:

1. The following tests are listed under "Other commercial tests": Altona FlexStar MP & CP PCR Detection Mix (1x), Anatolia GeneWorks Bosphore C. pneumoniae Detection Kit (1x), DNA-TECHNOLOGY C. pneumoniae, M. pneumoniae multiplex (1x), ELITechGroup Respiratory Bacterial ELITE MGB Panel (3x), Luminex NxTAG Respiratory Pathogen Panel + SARS-CoV-2 (1x), PathoFinder RespiFinder 2Smart (1x), Roche cobas 5800 (1x) and Vitassay qPCR Primary Atypical Pneumonia.